DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Non-Hodgkin Lymphoma
Conditions
Keywords
Lymphoma, Non-Hodgkin Lymphoma, DLBCL, Follicular Lymphoma, relapsed or refractory
Brief summary
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage, a combination stage, and a randomized dose-expansion stage where subjects will be enrolled into indication-specific expansion cohorts. imvotamab will be administered intravenously (IV). Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study.
Detailed description
Imvotamab is an engineered bispecific IgM antibody for the treatment of patients with CD20-positive cancers. It contains ten high affinity binding domains for CD20, and one binding domain for CD3. Imvotamab is able to eliminate CD20-positive lymphoma cells by engaging T-cells and lymphoma cells, leading to T-cell dependent cellular cytotoxicity. Additionally, imvotamab is also able to eliminate lymphoma cells by recruiting complement to the surface of lymphoma cells, leading to complement dependent cytotoxicity. In our preclinical studies, we observed activity against rituximab resistant cells carrying low levels of CD20. We have also observed much lower cytokine release with imvotamab relative to comparable IgG format bispecific T-cell engaging antibodies, which is expected to result in reduced risk of the serious adverse effects from cytokine release syndrome (CRS). For the combination stage, imvotamab will be combined with loncastuximab tesirine, a CD19-targeting antibody drug conjugate.
Interventions
DRUGimvotamab
Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
Sponsors
ADC Therapeutics S.A.
IGM Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * \> 18 years of age: ECOG PS 0 or 1 * Relapsed or Refractory Follicular Lymphoma (FL), and Diffuse Large B-cell Lymphoma (DLBCL), Mantle cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) in dose escalation * Relapsed or refractory to at least two prior systemic treatment regimens (must include anti-CD20 chemo-immunotherapy regimen). FL/MZL may be enrolled with a least 2 prior systemic regimens which must include an anti-CD20, without the need for a prior chemotherapy regimen) * At least one bi-dimensionally measurable lesion (\>1.5cm in it's longest dimension by computerized tomography (CT scan) * Good organ function * Not eligible for autologous stem cell transplant (DLBCL subjects), due to chemoresistant disease, medically unfit (organ function), or unwilling. Key
Exclusion criteria
* Prior allogeneic transplant * ASCT within 100 days prior to the first imvotamab administration. * Lack of response to prior treatment with CAR-T therapy, subjects with less than 3 months from prior CAR-T therapy to first dose of imvotamab, and prior CAR-T therapy only allowed with Medical Monitor approval. * Concurrent serious co-morbidities that could limit patients full participation and compliance. * Prior CD-targeting bispecific antibodies. * Prior loncastuximab tesirine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Frequency of Adverse Events | Baseline through approximately 30 days after last study treatment | Percentage of Adverse Events |
| Overall Response Rate (ORR) | Baseline up to 5 years | Percentage of measurable disease in subjects who have achieved either complete response (CR) or partial response (PR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Baseline up to 5 years | Percentage of measurable disease in subjects who have achieved either complete response (CR) or partial response (PR) |
| Duration of Response (DOR) | Baseline up to 5 years | measured from time of initial response until documented tumor progression |
Countries
Australia, Czechia, France, Italy, South Korea, Spain, United States
Outcome results
None listed